Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria | MicrobiomeTrials← Back to trialsNCT05270837
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2022-06-17Est. Completion: 2025-01-14
Enrollment target: 55 participants Locations- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- University of South Florida, Tampa, Florida, United States
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- IU Health University Hospital, Indianapolis, Indiana, United States
- University of Kentucky College of Medicine, Lexington, Kentucky, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States
- University of Utah Medical Center, Salt Lake City, Utah, United States
- University of Virginia School of Medicine, Charlottesville, Virginia, United States
- Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
- Charité - Universitätsmedizin Berlin, Berlin, Germany
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Other microbiome trials you might be interested in
Phenylketonuria
Phenylketonuria (PKU) is an inherited disorder of phenylalanine (Phe) metabolism. The mainstay of treatment is a Phe-res…
Birmingham, United KingdomEst. completion Dec 2026
Phenylketonuria
The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functio…
Indianapolis, United StatesEst. completion Feb 28, 2031
Universitat Mainz, Mainz, Germany